Easy to forget that the appetite we are silencing is not only biologicalit is human
Danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, will undergo dose optimization studies in the second half of 2024 as Pfizer seeks to evaluate multiple doses of the formulation which they hope will inform the registration-enabling studies
The cardiovascular and disease-modifying benefits seen in the 2025 studies typically emerge over months to a year of consistent use
Pendulum GLP-1 Probiotic Pro (practitioner version) Same formulation as the consumer version, but distributed through healthcare practitioners and specialty pharmacies
Zweck E, Westenfeld R, Szendroedi J
While mechanisms have been proposed, the full picture, including potential hormonal crosstalk and systemic influences like the gut-microbiota-brain axis, warrants dedicated future research